CHEMCD专业的化工医药类网站建设平台

  • HTML5,小绿锁,化工医药类
  • chemcd

Merck(www.merck.com)Gsk(www.gsk.com)Pfizerwww.pfizer.com, Novartiswww.novartis.com, Gileadwww.gilead.com你想拥有世界几大著名医药公司一样的网站吗?

那么就来加入我们吧!

(1).HTML5+JS建站

随着技术的更新换代,企业官网也是不断在改进。现在的建站市场,前瞻性的龙头企业已经在使用HTML5网站。HTML5技术实现了网站跨平台的应用,这样可以增加用户流量,尤其移动设备的多样化,包括了各种屏幕大小的手机,平板等等,毫无疑问,在互联网的趋势下,大半的用户流量将来源于移动终端的用户。而HTML5很好地兼容了各种浏览器,让网站的呈现效果不会因设备的不同而改变,大大提高了用户体验

ChemCD专门从事医药化工类网站制作,网站完全采用定制化开发思路HTML5+JS建站技术支持PC版本及终端版本,中英文版面,赠送域名+企业邮箱服务器节点遍布中国,美国,日本,欧洲,香港等地区。我们拥有丰富的网站建设经验,专业化的设计开发团队将为您量身定制个性化、精美完善的企业网站。

这是我们为一些公司定制的网站:


http://www.sun-shinebio.com/


http://www.nextpeptide.com/


http://www.boroncore.com/


http://www.stepuppharm.com/


http://www.uftide.com/


https://www.capotchem.com/


http://www.keyingchem.com/



http://www.yudiaochem.com/





(2).HTTPS加密功能

另外我们还可以为您的网站提供安全的加密功能,在HTTP开头的网站输入信用卡号、交易密码等机密信息等有可能会被窃取,但是HTTPS开头的网址就不一样了,此时用户在线输入的信用卡号、交易密码等机密信息在网络传输过程中将不会被查看、窃取和修改。所以安全的网址前面会有一个小绿锁的标志。如下图,点击会显示该网站安全,提示您可以放心浏览该网站,相反不会显示小绿锁,点击的话会提示该网站不安全,提示您小心。同时HTTPS开头的网址优先会被Google及百度收录,而HTTP在Google排名会靠后,在百度中完全不会收录。

为了客户及自身的安全,HTTPS势在必行,是时候为你的站点加上“小绿锁”了。



您想拥有一个既精美又安全的网站吗?那么快来联系我们吧!

扫描下方二维码,关注微信公众号,我们将抽取10位幸运客户获得网站体验大礼包!




ChemCD

电话:0571-8102528013588292446

QQ 320204646

网址:www.chemcd.com

邮箱:j.king@chemcd.com


This link:http://www.chemcd.com/news/37635.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.